Crossmark

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Crossref DOI link: https://doi.org/10.1186/s40425-019-0680-3

Published Online: 2019-07-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zimmer, Alexandra S. https://orcid.org/0000-0001-6789-0982
Nichols, Erin

Cimino-Mathews, Ashley

Peer, Cody

Cao, Liang

Lee, Min-Jung

Kohn, Elise C.

Annunziata, Christina M.

Lipkowitz, Stanley

Trepel, Jane B.

Sharma, Rajni

Mikkilineni, Lekha

Gatti-Mays, Margaret

Figg, William D.

Houston, Nicole D.

Lee, Jung-Min
Funding

Funding for this research was provided by:

National Cancer Institute, National Institutes of Health (Contract No. HHSN261200800001E)
License Information

Text and Data Mining valid from 2019-07-25
More Information

Article History

Received: 6 May 2019

Accepted: 16 July 2019

First Online: 25 July 2019

Ethics approval and consent to participate

: This clinical trial was approved by the NIH IRB.

: All patients enrolled in the clinical trial signed Informed Consent.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below